Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

The antidepressant agomelatine in daily practice: results of the non-interventional study VIVALDI.

Laux G; VIVALDI Study Group..

Pharmacopsychiatry. 2012 Nov;45(7):284-91. doi: 10.1055/s-0032-1309003. Epub 2012 May 16.

PMID:
22592503
2.

Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline.

Kasper S, Hajak G, Wulff K, Hoogendijk WJ, Montejo AL, Smeraldi E, Rybakowski JK, Quera-Salva MA, Wirz-Justice AM, Picarel-Blanchot F, Baylé FJ.

J Clin Psychiatry. 2010 Feb;71(2):109-20. doi: 10.4088/JCP.09m05347blu.

PMID:
20193645
3.

Subgroup analysis of the non-interventional study VIVALDI: agomelatine in treatment-naïve patients, in combination therapy and after treatment switch.

Laux G, Huttner NA; VIVALDI study group..

Int J Psychiatry Clin Pract. 2014 Jun;18(2):86-96. doi: 10.3109/13651501.2014.892138. Epub 2014 Mar 28.

PMID:
24506342
4.

Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study.

Hale A, Corral RM, Mencacci C, Ruiz JS, Severo CA, Gentil V.

Int Clin Psychopharmacol. 2010 Nov;25(6):305-14. doi: 10.1097/YIC.0b013e32833a86aa.

PMID:
20856123
5.

Agomelatine in the treatment of seasonal affective disorder.

Pjrek E, Winkler D, Konstantinidis A, Willeit M, Praschak-Rieder N, Kasper S.

Psychopharmacology (Berl). 2007 Mar;190(4):575-9. Epub 2006 Dec 15.

PMID:
17171557
6.
7.

The efficacy of agomelatine in elderly patients with recurrent major depressive disorder: a placebo-controlled study.

Heun R, Ahokas A, Boyer P, Giménez-Montesinos N, Pontes-Soares F, Olivier V; Agomelatine Study Group..

J Clin Psychiatry. 2013 Jun;74(6):587-94. doi: 10.4088/JCP.12m08250.

PMID:
23842010
8.

Comparable efficacy and safety of 8 weeks treatment with agomelatine 25-50mg or fluoxetine 20-40mg in Asian out-patients with major depressive disorder.

Shu L, Sulaiman AH, Huang YS, Fones Soon Leng C, Crutel VS, Kim YS.

Asian J Psychiatr. 2014 Apr;8:26-32. doi: 10.1016/j.ajp.2013.09.009. Epub 2013 Sep 30.

PMID:
24655622
9.

Treating each and every depressed patient.

Kennedy SH.

J Psychopharmacol. 2008 Sep;22(7 Suppl):19-23. doi: 10.1177/0269881108093270. Review.

PMID:
18753279
10.

Agomelatine in elderly--finally a patient friendly antidepressant in psychogeriatry?

Lužný J.

Actas Esp Psiquiatr. 2012 Nov-Dec;40(6):304-7. Epub 2012 Nov 1.

11.

The efficacy of agomelatine in previously-treated depressed patients.

Kasper S, Hajak G.

Eur Neuropsychopharmacol. 2013 Aug;23(8):814-21. doi: 10.1016/j.euroneuro.2013.05.010. Epub 2013 Jun 29.

PMID:
23820051
12.

Impact of the novel antidepressant agomelatine on disturbed sleep-wake cycles in depressed patients.

Quera-Salva MA, Lemoine P, Guilleminault C.

Hum Psychopharmacol. 2010 Apr;25(3):222-9. doi: 10.1002/hup.1112. Review.

PMID:
20373473
13.

Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action.

Kasper S, Hamon M.

World J Biol Psychiatry. 2009;10(2):117-26. doi: 10.1080/15622970902717024. Review.

PMID:
19255935
14.

Efficacy and tolerance profile of agomelatine and practical use in depressed patients.

Rouillon F.

Int Clin Psychopharmacol. 2006 Feb;21 Suppl 1:S31-5.

PMID:
16436938
15.

Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial.

Zajecka J, Schatzberg A, Stahl S, Shah A, Caputo A, Post A.

J Clin Psychopharmacol. 2010 Apr;30(2):135-44. doi: 10.1097/JCP.0b013e3181d420a7.

PMID:
20520286
16.
20.

Addressing circadian rhythm disturbances in depressed patients.

Lam RW.

J Psychopharmacol. 2008 Sep;22(7 Suppl):13-8. doi: 10.1177/0269881108092591. Review.

PMID:
18753278

Supplemental Content

Support Center